JKS Document Store
 Store FrontAccountSearchProduct ListBasket Contents Checkout 
Search For The Following Word(s):
Sign In

Medicinal Products Lifecycle
Medical Devices
Japan Monitor (ISSN 1550-3429)
Information Meetings
Legislation and Agreements
All in Japan (ISSN 1550-3402)
E-health Japan (ISSN 1550-3410)
EU Pharma & Medical Devices
Free documents

All in Japan: Statins (Single User License)

All in Japan: Statins (Single User License)Quantity in Basket:none
Code: AJ_T_003

ISSN 1550-3402 (Single User License) 118-page document. <<>> Preamble: The reports from the "All in Japan" series provide overview and concise up-to-date description of each product from a specific product or therapeutic category approved in Japan. All in Japan: Statins report is the largest so far in the All in Japan series, a long awaited regulatory compendium on the top selling drug class in Japan. The report cross-examines the Japanese statin regulatory market in terms of therapeutic, formulation, registration and regulatory classification along with full listing of approval, pricing and market timelines and even manufacturer premises. With clear tabulated format, the explosion of pravastatin generic approvals in 2003 concomitantly with the patent expiry of Sankyo's blockbuster Mevalotin® cannot go unnoticed in this report. The pravastatin scenario has had a domino effect on simvastatin manufacturers and/or their respective marketing agents in filing for generic approval, culminating in 44 "me too" registered statin generics representing a staggering 86% of the total statin drugs available today on the Japanese prescription registry. <<>> Key Features: *Unprecedented full regulatory findings on all 51 registered statin prescription medicines currently available in Japan; *Key package insert information and formulation specification and precise drawn-to-scale graphical representation of the 51 products for quick referencing; *Expert generated statistical and graphical findings for convenient regulatory and strategic research use; *Tabulated easy-to-find alphabetical listing previously unavailable in English. <<>> Analysis Highlights: Although New Chemical Entity statins innovated from Japan pharma will continue to buoy the dyslipidemia market, with a 55% stake of all Japan registered statins, pravastatin continues to be the mainstay. An obvious concern for new entrants is an over-saturation of Japan registered statins generics, and expiry of the Mevalotin® patent in July 2003 saw the floodgates open with Japan registered statins pravastatin and simvastatin generic numbers climbing to 27 and 17 respectively a 44 strong generic "tsunami" comprising of 86% of the total Japan registered statins market. With the Japanese prescription registry being expanded to pitavastatin calcium and increased availability of adjunctive therapies, no doubt this will lead to major improvements in the treatment of more "difficult-to-treat" patients. <<>> Practical Use to the Reader: *To champion opportunities in the Statin market, strengthen internal positioning of dyslipidemia pipeline portfolio, and identify lucrative licensing and co-marketing opportunities - this report is a must for product managers wanting to enter the Japanese market; *Regulatory affairs personnel seeking regulatory approval for their cardiovascular product in Japan - an indispensable information source particularly for benchmarking their own product with the Japanese market in terms of approval timeline and registration feasibility; *Statin marketing specialists can evaluate (or reevaluate) their Japan strategy by having access to regulatory information normally unavailable elsewhere; *Invaluable reference material to confirm or refute current concerns arising from your organization's regulatory strategy to register a statin generic in Japan. <<>> Copyright © JKS LLC 2004.

Related Item(s)
Code Name Price    
AJ_T_001All in Japan: Triptans (Single User License) $425.00
AJ_T_004All in Japan: Statins (Enterprise-wide Use License) $7,500.00
AJ_T_002All in Japan: Triptans (Enterprise-wide Use License) $1,950.00
AJ_T_005All in Japan: Anti-cancers (Single User License) $1,250.00
AJ_T_006All in Japan: Anti-cancers (Enterprise-wide Use License) $4,250.00
AJ_T_007All in Japan: Statins 2005 (Single User License) $350.00